This product is supplied in powder form with a minum purity of 98%. This material is not a pelleted item, nor are there any excipients or salts added.
Fortfahren mit
SML1491
GW501516
≥98% (HPLC), PPARδ agonist, powder
Synonym(e):
2-[2-Methyl-4-[[[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]methyl]thio]phenoxy]-acetic acid, GW1516
Anmelden zur Ansicht der Organisations- und Vertragspreise.
Größe auswählen
Ansicht ändern
| Ihnen/SKU | Verfügbarkeit | Preis |
|---|---|---|
5 mg | Warenkorb auf Verfügbarkeit prüfen | € 131,00 |
25 mg | Warenkorb auf Verfügbarkeit prüfen | € 524,00 |
Über diesen Artikel
Empirische Formel (Hill-System):
C21H18F3NO3S2
CAS-Nummer:
Molekulargewicht:
453.50
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77
MDL number:
Assay:
≥98% (HPLC)
Form:
powder
Technischer Dienst
Benötigen Sie Hilfe? Unser Team von erfahrenen Wissenschaftlern ist für Sie da.
Unterstützung erhaltenProduktname
GW501516, ≥98% (HPLC)
Quality Segment
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 20 mg/mL, clear
storage temp.
−20°C
SMILES string
FC(F)(F)c1ccc(cc1)c2[s]c(c(n2)C)CSc3cc(c(cc3)OCC(=O)O)C
InChI
1S/C21H18F3NO3S2/c1-12-9-16(7-8-17(12)28-10-19(26)27)29-11-18-13(2)25-20(30-18)14-3-5-15(6-4-14)21(22,23)24/h3-9H,10-11H2,1-2H3,(H,26,27)
InChI key
YDBLKRPLXZNVNB-UHFFFAOYSA-N
Application
GW501516 has been used as a peroxisome proliferator-activated receptor (PPAR) δ agonist:
- to treat the differentiated L6 myotubes to test its effect on free fatty acid (FFA) uptake under mild hypoxia conditions[1]
- in organoid culture medium to test its effect on self-renewal of PR domain containing 16 (Prdm16)-depleted intestinal stem cells[2]
- as a component in the defatting medium for primary human hepatocytes (PHH) culture[3]
GW501516 has been used to study its effect on mutation-driven colorectal tumorigenesis and tumor invasion using mouse model.
Biochem/physiol Actions
GW501516 is a selective Peroxisome Proliferator-Activated Receptor delta (PPARδ) agonist with high affinity (Ki = 1 nM) and potency (EC50 = 1 nM) for PPARδ and > 1000 fold selectivity over PPARα and PPARγ. GW501516 was shown to activate some of the same pathways activated through exercise, and was investigated as a potential treatment for obesity, diabetes, dyslipidemia and cardiovascular disease. However, GW501516 also showed an increase in cancer in rats.
GW501516 is a selective Peroxisome Proliferator-Activated Receptor delta (PPARδ) agonist.
PPARδ activation by GW501516, retards weight gain through fatty acid catabolism in adipose tissue and skeletal muscles. GW501516 causes an increase in the levels high-density lipoprotein cholesterol and apolipoprotein A (apoA) and reduction in the low density-lipoprotein cholesterol, apoB, and triglyceride.
1 of 1
Dieser Artikel | |||
|---|---|---|---|
| form powder | form powder | form powder | form powder |
| assay ≥98% (HPLC) | assay ≥98% (HPLC) | assay ≥95% (HPLC) | assay ≥98% (HPLC) |
| Quality Level 100 | Quality Level 100 | Quality Level 100 | Quality Level 100 |
| storage temp. −20°C | storage temp. 2-8°C | storage temp. room temp | storage temp. 2-8°C |
| solubility DMSO: 20 mg/mL, clear | solubility DMSO: >5 mg/mL, H2O: insoluble | solubility DMSO: 5 mg/mL, clear (warmed) | solubility DMSO: ≥5 mg/mL at ~60 °C |
| color white to beige | color white | color white to beige | color white to tan |
Lagerklasse
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Hier finden Sie alle aktuellen Versionen:
Besitzen Sie dieses Produkt bereits?
In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.
-
Hello I was wondering about your 5mg quantity, is it 5mg in total or 5mg research pellets?
1 answer-
Helpful?
-
-
Which solvent is suitable for reconstituting item B7273, Bezafibrate?
1 answer-
B7273, Bezafibrate can be dissolved in DMSO (50 mg/ml), water (partly), methanol, ethanol (~3 mg/ml), and DMF (~30 mg/ml).
Helpful?
-